CVS Health announced comprehensive GLP-1 support across 9,000 CVS Pharmacy locations and MinuteClinic, available virtually nationwide.
New offerings include expanded pharmacy support for patients accessing treatments. CVS introduced $49 MinuteClinic virtual visit connecting eligible adults with licensed clinicians for GLP-1 evaluation and prescription.
The approach combines lower-cost access, personalized pharmacist support, and over-the-counter products managing common side effects, addressing three biggest barriers to GLP-1 therapy.
CVS will participate in Centers for Medicare & Medicaid Services’ Medicare GLP-1 Bridge Program starting July 1, offering eligible beneficiaries select GLP-1 medications for $50 monthly through December 31, 2027.
Effective June 1, CVS Caremark removed new-to-market block on Foundayo, signaling company’s willingness embracing emerging treatments.
Timing is strategic. GLP-1 medications increasingly popular for weight management, demand far exceeds supply. CVS’s pharmacy network and clinical infrastructure position company capturing market share from online competitors.
Bank of America raised CVS stock price target on GLP-1 expansion, signaling investor confidence. Program represents shift in how traditional healthcare retailers adapt competing in AI-era healthcare market.
Follow iNews Zoombangla On Google
Open the Google follow page and tap the checkmark option to receive more updates from iNews Zoombangla in your Google news feed.
